Jeffrey M. Leiden - 06 Feb 2024 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Executive Chairman, Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
06 Feb 2024
Net transactions value
$0
Form type
4
Filing time
08 Feb 2024, 16:40:41 UTC
Previous filing
10 Jan 2024
Next filing
12 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +10,464 +432% $0.000000 12,887 06 Feb 2024 Direct F1
transaction VRTX Common Stock Award $0 +20,452 +159% $0.000000 33,339 06 Feb 2024 Direct F2
transaction VRTX Common Stock Award $0 +7,707 +23% $0.000000 41,046 07 Feb 2024 Direct F3
holding VRTX Common Stock 440 06 Feb 2024 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024.
F2 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/10/2024.
F3 Restricted stock unit award that fully vested upon grant.